筑波硼中子俘获疗法试验的现状：基于双对氨基苯甲醚的硼中子俘获疗法联合X射线照射。
The status of Tsukuba BNCT trial: BPA-based boron neutron capture therapy combined with X-ray irradiation.
作者信息
Yamamoto T, Nakai K, Nariai T, Kumada H, Okumura T, Mizumoto M, Tsuboi K, Zaboronok A, Ishikawa E, Aiyama H, Endo K, Takada T, Yoshida F, Shibata Y, Matsumura A
机构信息
Department of Neurosurgery, Graduate School of Comprehensive Human Science, University of Tsukuba, Tennodai, Tsukuba, Japan.
出版信息
Appl Radiat Isot. 2011 Dec;69(12):1817-8. doi: 10.1016/j.apradiso.2011.02.013. Epub 2011 Feb 15.
The phase II trial has been prepared to assess the effectiveness of BPA (250 mg/kg)-based NCT combined with X-ray irradiation and temozolomide (75 mg/m(2)) for the treatment of newly diagnosed GBM. BPA uptake is determined by (18)F-BPA-PET and/or (11)C-MET-PET, and a tumor with the lesion to normal ratio of 2 or more is indicated for BNCT. The maximum normal brain point dose prescribed was limited to 13.0 Gy or less. Primary end point is overall survival.
已准备好进行II期试验，以评估基于双酚A（250毫克/千克）的硼中子俘获疗法（BNCT）联合X射线照射和替莫唑胺（75毫克/平方米）治疗新诊断的胶质母细胞瘤（GBM）的有效性。通过（18）F - 双酚A - 正电子发射断层扫描（PET）和/或（11）C - 蛋氨酸 - PET测定双酚A摄取情况，病变与正常组织比值为2或更高的肿瘤适用于硼中子俘获疗法。规定的最大正常脑点剂量限制在13.0戈瑞或更低。主要终点是总生存期。
Zotero 插件